Author

Juliane Sueptitz

Observed names: J. Sueptitz, J. Süptitz, Juliane Süptitz, Sueptitz, J., Sueptitz, Juliane, Süptitz, Juliane

Observed institutions: University of Cologne, University Hospital Cologne

OpenAlex ID: A5025764998

Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM)

2022 · M. Janning, J. Süptitz, et al. · Annals of Oncology · 94

Genetic Heterogeneity of MET-Aberrant NSCLC and Its Impact on the Outcome of Immunotherapy

2020 · Anna Kron, Matthias Scheffler, et al. · Journal of Thoracic Oncology · 72

Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1–High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer

2023 · Philip Bischoff, Martin Reck, et al. · Journal of Thoracic Oncology · 52

Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors

2020 · Svenja Wagener-Ryczek, Carina Heydt, et al. · BMC Cancer · 31

Survival following implementation of next-generation sequencing in routine diagnostics of advanced lung cancer: Results of the German Network Genomic Medicine.

2016 · Anna Kostenko, Sebastian Yves Friedrich Michels, et al. · Journal of Clinical Oncology · 7

Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors

2019 · S. Wagener-Ryczek, C. Heydt, et al. · Annals of Oncology · 6

Treatment outcome and functional characterization of uncommon EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM).

2021 · Melanie Janning, Juliane Sueptitz, et al. · Journal of Clinical Oncology · 2

991P EGFR exon 20 insertions in non-small cell lung cancer (NSCLC): Impact of TP53 mutation status and value of immune checkpoint blockade (ICB)

2022 · A. Kron, M. Scheffler, et al. · Annals of Oncology · 1

Screening of FGFR patients for FGFR directed clinical trials in Network Genomic Medicine (NGM): Real-world data.

2022 · Heather Scharpenseel, Florian Malchers, et al. · Journal of Clinical Oncology · 1

The network genomic medicine cost reimbursement model for implementation of comprehensive lung cancer genotyping in clinical routine.

2015 · Anna Kostenko, Jan Peter Glossmann, et al. · Journal of Clinical Oncology · 1

Additional file 1 of Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors

2020 · Wagener-Ryczek, Svenja, Heydt, Carina, et al. · Figshare

3006 Broad implementation of next generation sequencing based lung cancer genotyping in clinical routine within a nationwide health care provider network in Germany

2015 · A. Kostenko, F. Kron, et al. · European Journal of Cancer

Works count: 22

Citation count: 267

H-index: 6

I10-index: 4